- Home
- PIPR vs AKRO Comparison
PIPR vs AKRO Comparison
Compare PIPR & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIPR
- AKRO
- Stock Information
- Founded
- PIPR 1895
- AKRO 2017
- Country
- PIPR United States
- AKRO United States
- Employees
- PIPR N/A
- AKRO N/A
- Industry
- PIPR Investment Bankers/Brokers/Service
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- PIPR Finance
- AKRO Health Care
- Exchange
- PIPR Nasdaq
- AKRO Nasdaq
- Market Cap
- PIPR 4.2B
- AKRO 3.9B
- IPO Year
- PIPR N/A
- AKRO 2019
- Fundamental
- Price
- PIPR $301.19
- AKRO $51.69
- Analyst Decision
- PIPR Hold
- AKRO Strong Buy
- Analyst Count
- PIPR 4
- AKRO 6
- Target Price
- PIPR $312.50
- AKRO $82.50
- AVG Volume (30 Days)
- PIPR 171.7K
- AKRO 1.6M
- Earning Date
- PIPR 08-01-2025
- AKRO 08-08-2025
- Dividend Yield
- PIPR 1.86%
- AKRO N/A
- EPS Growth
- PIPR 93.72
- AKRO N/A
- EPS
- PIPR 11.46
- AKRO N/A
- Revenue
- PIPR $1,540,130,000.00
- AKRO N/A
- Revenue This Year
- PIPR $8.46
- AKRO N/A
- Revenue Next Year
- PIPR $17.89
- AKRO N/A
- P/E Ratio
- PIPR $26.31
- AKRO N/A
- Revenue Growth
- PIPR 10.55
- AKRO N/A
- 52 Week Low
- PIPR $202.91
- AKRO $21.34
- 52 Week High
- PIPR $351.80
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- PIPR 70.29
- AKRO 45.35
- Support Level
- PIPR $284.78
- AKRO $50.13
- Resistance Level
- PIPR $294.98
- AKRO $53.60
- Average True Range (ATR)
- PIPR 6.80
- AKRO 2.03
- MACD
- PIPR 1.70
- AKRO -0.83
- Stochastic Oscillator
- PIPR 97.57
- AKRO 6.37
About PIPR Piper Sandler Companies
Piper Sandler Cos is an investment bank and institutional securities firm, serving the needs of corporations, private equity groups, public entities, non-profit entities and institutional investors in the United States (U.S.) and internationally. The company provides a broad set of products and services, including financial advisory services; equity and debt capital markets products; public finance services; institutional brokerage services; fundamental equity and macro research services; fixed income services; and alternative asset management strategies. It generates maximum revenue from Advisory services followed by Equity financing.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.